GIS:FRA
Gilead Sciences, Inc
154,18 €
arrow_downward
−0,67%(−1,04) 1D
17. nov., 22:00:00 GMT +1 · EUR
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za GIS …
Odpri
151,84 €
Visoka
155,24 €
Nizka
151,84 €
Tržna kapitalizacija
211,18 mrd.
Povprečni promet
224,00
Promet
674,00
52-tedenski najvišji tečaj
157,14 €
52-tedenski najnižji tečaj
100,42 €
Št. zaposlenih
17 tis.
Odpri
151,84 €
Visoka
155,24 €
Nizka
151,84 €
Tržna kapitalizacija
211,18 mrd.
Povprečni promet
224,00
Promet
674,00
52-tedenski najvišji tečaj
157,14 €
52-tedenski najnižji tečaj
100,42 €
Št. zaposlenih
17 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
MarketWatch
·
pred 3 urami
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Unitaid
·
pred 7 urami
Access planning for Ebola medicines moves ahead during clinical trials
Yahoo Finance
·
pred 8 urami
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
Yahoo Finance
·
pred 9 urami
Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Vizitka: Gilead Sciences, Inc
Generalni direktorDaniel O'Day
Št. zaposlenih17 tis.
Ustanovljeno22. jun. 1987
SedežFoster City, Kalifornija, Združene države Amerike
SektorHealth Care
Panoga-
Spletno mestogilead.com